We found that clonal CD34<sup>+</sup>/CD38<sup>-</sup> stem cells, CD34<sup>+</sup>/CD38<sup>+</sup> progenitor cells, and CD117<sup>++</sup>/CD34<sup>-</sup> MCs invariably express CD44 in patients with indolent SM (ISM), SM with an associated hematologic neoplasm, aggressive SM, and MC leukemia (MCL).
This study provides a proof-of-concept that lipoic acid-crosslinked hyaluronic acid nanoparticulate drugs may offer a more safe and effective treatment modality for CD44 positive hematological malignancies.
In conclusion, our results indicate that among investigated single nucleotide polymorphisms (SNPs), only CD44rs13347 has an impact on the efficacy of HSCs mobilization in patients with hematologic malignancies.
We determined whether these side effects could be avoided by replacing anti-panCD44 with CD44 variant isoform (CD44v)-specific antibodies in CD44v-positive hematological malignancies using the EL4 thymoma and CD44v10-transfected EL4 (EL4-v10) as models.
The expression of variant forms of CD44, particularly forms containing exon v6, have been associated with poor prognosis in a number of hematological malignancies.